Roxadustat for Treatment of Anemia in a Cancer Patient with Endstage Renal Disease: A Case Report

BACKGROUND Most cancer patients are accompanied by anemia, which will be more serious when combined with end-stage renal disease（ESRD）. At present, cancer-related anemia and renal anemia treatments mainly include erythropoiesis-stimulating agents（ESAs）, iron supplementation, and blood transfusion, but their effects are often poor with several safety concerns. We have used roxadustat to treat anemia in a cancer patient with ESRD and achieved a successful outcome for the first time.CASE SUMMARY A 64-year-old man was diagnosed with right renal cancer（clear cell renal cell carcinoma）. He did not receive surgery or radiotherapy before admission. He was treated with oral soltan（sunitinib malate） on April 18, 2017. During oral chemotherapy, he had numerous complications, including anemia, hypertension, thyroid hypofunction, skin pigment loss, and renal function deterioration. At last, he progressed to ESRD and began hemodialysis treatment. We initially treated the patient with high-dose ESAs, iron supplementation, adequate dialysis, and even blood transfusion, but his anemia did not improve. Roxadustat is a newly developed drug for renal anemia treatment, but not for cancer-related anemia, let alone to treat anemia in cancer patients with ESRD. We prescribed oral roxadustat to the patient. After a period, his hemoglobin gradually increased. He did not have obvious discomfort symptoms, and his tumor did not progress significantly.CONCLUSION Oral roxadustat could achieve good results in treating anemia in cancer patients with ESRD.